Table 1.
Cases Ref | 13 | 22 | 39 | 44 | 54 | 65 | 76 | 86 | 914 |
---|---|---|---|---|---|---|---|---|---|
| |||||||||
Age (y) | 21 | 46 | 34 | 44 | 26 | 34 | 37 | 43 | 48 |
Sex | Female | Female | Female | Female | Female | Female | Female | Female | Female |
Residence | Africa | Pakistan | Mainland China | Pakistan | Pakistan | Indonesia | Mainland China | Mainland China | South Africa |
Diagnosis place | Africa | England | Hong Kong | England | England | Hong Kong | Mainland China | Mainland China | South Africa |
Duration of cream use (mo) | 24.00 | 36.00 | 4.00 | Unspecified | Unspecified | 60.00 | 12.00 | 8.00 | 96.00 |
Frequency of cream use | Every day | Every day | Every day | Unspecified | Unspecified | Every day | Unspecified | Unspecified | Unspecified |
Renal pathology | MN | MN | MCD | MN | MN | MN | MN | MN | Chronic proliferative glomerulonephritis |
24 h Protein (g/d) | 10.00 | 2.20 | 8.35 | Unspecified | 9.00 | 4.90 | 3.82 | 3.52 | 7.00 |
Times of urine mercury above normal (mo) | Unspecified | Unspecified | 5.74 | 3.00 | Unspecified | 75.46 | 12.50 | 2.25 | Unspecified |
Times of blood mercury above normal (mo) | Unspecified | Unspecified | 2.48 | 5.00 | 7.76 | 3.26 | Unspecified | Unspecified | Unspecified |
Renal function | Normal | Normal | Normal | Abnormal | Unspecified | Normal | Normal | Normal | Normal |
Treatment | Unspecified | glucocoticoid | Mercury detoxification | Unspecified | Unspecified | Unspecified | ACEI | ARB | Unspecified |
Outcome | Unspecified | Unspecified | Cured | Unspecified | Unspecified | Unspecified | Cured | Cured | Unspecified |
MN: Membrane nephropathy, MCD: minimal change disease,[AUTHOR: Please provide the full forms of ACEI and ARB.].